Cargando…

Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis

BACKGROUND: Observational studies have reported higher mortality among older adults treated with first-generation antipsychotics (FGAs) versus second-generation antipsychotics (SGAs). A few studies examined risk for medical events, including stroke, ventricular arrhythmia, venous thromboembolism, my...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, John W., Schneeweiss, Sebastian, VanderWeele, Tyler J., Blacker, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139353/
https://www.ncbi.nlm.nih.gov/pubmed/25140533
http://dx.doi.org/10.1371/journal.pone.0105376
_version_ 1782331353039110144
author Jackson, John W.
Schneeweiss, Sebastian
VanderWeele, Tyler J.
Blacker, Deborah
author_facet Jackson, John W.
Schneeweiss, Sebastian
VanderWeele, Tyler J.
Blacker, Deborah
author_sort Jackson, John W.
collection PubMed
description BACKGROUND: Observational studies have reported higher mortality among older adults treated with first-generation antipsychotics (FGAs) versus second-generation antipsychotics (SGAs). A few studies examined risk for medical events, including stroke, ventricular arrhythmia, venous thromboembolism, myocardial infarction, pneumonia, and hip fracture. OBJECTIVES: 1) Review robust epidemiologic evidence comparing mortality and medical event risk between FGAs and SGAs in older adults; 2) Quantify how much these medical events explain the observed mortality difference between FGAs and SGAs. DATA SOURCES: Pubmed and Science Citation Index. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Studies of antipsychotic users that: 1) evaluated mortality or medical events specified above; 2) restricted to populations with a mean age of 65 years or older 3) compared FGAs to SGAs, or both to a non-user group; (4) employed a “new user” design; (5) adjusted for confounders assessed prior to antipsychotic initiation; (6) and did not require survival after antipsychotic initiation. A separate search was performed for mortality estimates associated with the specified medical events. STUDY APPRAISAL AND SYNTHESIS METHODS: For each medical event, we used a non-parametric model to estimate lower and upper bounds for the proportion of the mortality difference—comparing FGAs to SGAs—mediated by their difference in risk for the medical event. RESULTS: We provide a brief, updated summary of the included studies and the biological plausibility of these mechanisms. Of the 1122 unique citations retrieved, we reviewed 20 observational cohort studies that reported 28 associations. We identified hip fracture, stroke, myocardial infarction, and ventricular arrhythmias as potential intermediaries on the causal pathway from antipsychotic type to death. However, these events did not appear to explain the entire mortality difference. CONCLUSIONS: The current literature suggests that hip fracture, stroke, myocardial infarction, and ventricular arrhythmias partially explain the mortality difference between SGAs and FGAs.
format Online
Article
Text
id pubmed-4139353
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41393532014-08-25 Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis Jackson, John W. Schneeweiss, Sebastian VanderWeele, Tyler J. Blacker, Deborah PLoS One Research Article BACKGROUND: Observational studies have reported higher mortality among older adults treated with first-generation antipsychotics (FGAs) versus second-generation antipsychotics (SGAs). A few studies examined risk for medical events, including stroke, ventricular arrhythmia, venous thromboembolism, myocardial infarction, pneumonia, and hip fracture. OBJECTIVES: 1) Review robust epidemiologic evidence comparing mortality and medical event risk between FGAs and SGAs in older adults; 2) Quantify how much these medical events explain the observed mortality difference between FGAs and SGAs. DATA SOURCES: Pubmed and Science Citation Index. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Studies of antipsychotic users that: 1) evaluated mortality or medical events specified above; 2) restricted to populations with a mean age of 65 years or older 3) compared FGAs to SGAs, or both to a non-user group; (4) employed a “new user” design; (5) adjusted for confounders assessed prior to antipsychotic initiation; (6) and did not require survival after antipsychotic initiation. A separate search was performed for mortality estimates associated with the specified medical events. STUDY APPRAISAL AND SYNTHESIS METHODS: For each medical event, we used a non-parametric model to estimate lower and upper bounds for the proportion of the mortality difference—comparing FGAs to SGAs—mediated by their difference in risk for the medical event. RESULTS: We provide a brief, updated summary of the included studies and the biological plausibility of these mechanisms. Of the 1122 unique citations retrieved, we reviewed 20 observational cohort studies that reported 28 associations. We identified hip fracture, stroke, myocardial infarction, and ventricular arrhythmias as potential intermediaries on the causal pathway from antipsychotic type to death. However, these events did not appear to explain the entire mortality difference. CONCLUSIONS: The current literature suggests that hip fracture, stroke, myocardial infarction, and ventricular arrhythmias partially explain the mortality difference between SGAs and FGAs. Public Library of Science 2014-08-20 /pmc/articles/PMC4139353/ /pubmed/25140533 http://dx.doi.org/10.1371/journal.pone.0105376 Text en © 2014 Jackson et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jackson, John W.
Schneeweiss, Sebastian
VanderWeele, Tyler J.
Blacker, Deborah
Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis
title Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis
title_full Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis
title_fullStr Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis
title_full_unstemmed Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis
title_short Quantifying the Role of Adverse Events in the Mortality Difference between First and Second-Generation Antipsychotics in Older Adults: Systematic Review and Meta-Synthesis
title_sort quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139353/
https://www.ncbi.nlm.nih.gov/pubmed/25140533
http://dx.doi.org/10.1371/journal.pone.0105376
work_keys_str_mv AT jacksonjohnw quantifyingtheroleofadverseeventsinthemortalitydifferencebetweenfirstandsecondgenerationantipsychoticsinolderadultssystematicreviewandmetasynthesis
AT schneeweisssebastian quantifyingtheroleofadverseeventsinthemortalitydifferencebetweenfirstandsecondgenerationantipsychoticsinolderadultssystematicreviewandmetasynthesis
AT vanderweeletylerj quantifyingtheroleofadverseeventsinthemortalitydifferencebetweenfirstandsecondgenerationantipsychoticsinolderadultssystematicreviewandmetasynthesis
AT blackerdeborah quantifyingtheroleofadverseeventsinthemortalitydifferencebetweenfirstandsecondgenerationantipsychoticsinolderadultssystematicreviewandmetasynthesis